Carbonic anhydrase IX expression in clear cell renal cell carcinoma and normal tissues: Experiences from (radio) immunotherapy

Journal of Clinical Oncology

Volumn 26, Issue 22, 2008, Pages 3808-3809

  Brouwers, Adrienne H ^a   Mulders, Peter F A ^b   Oyen, Wim J G ^b  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CARBONATE DEHYDRATASE IX; CA9 PROTEIN, HUMAN; CARBONATE DEHYDRATASE; DIAGNOSTIC AGENT; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY G250; RADIOACTIVE IODINE; TUMOR ANTIGEN; TUMOR MARKER;

CANCER RISK; CLEAR CELL CARCINOMA; KIDNEY CARCINOMA; LETTER; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOIMMUNOTHERAPY; ENZYMOLOGY; HUMAN; IMMUNOLOGY; KIDNEY TUMOR; NOTE; SCINTISCANNING; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; CARBONIC ANHYDRASES; CARCINOMA, RENAL CELL; HUMANS; IODINE RADIOISOTOPES; KIDNEY NEOPLASMS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 49249101335     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.17.6073     Document Type: Letter

References (14)

1. Leibovich BC, Sheinin Y, Lohse CM, et al: Carbonic anhydrase IX is not an independent predictor of outcome for patients with clear cell renal cell carcinoma. J Clin Oncol 25:4757-4664, 2007
2. Bui MH, Seligson D, Han KR, et al: Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: Implications for prognosis and therapy. Clin Cancer Res 9:802-811, 2003
3. Bui MH, Visapaa H, Seligson D, et al: Prognostic value of carbonic anhydrase IX and KI67 as predictors of survival for renal clear cell carcinoma. J Urol 171:2461-2466, 2004
4. Ivanov S, Liao SY, Ivanova A, et al: Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer. Am J Pathol 158:905-919, 2001
5. Oosterwijk E, Ruiter DJ, Hoedemaeker PJ, et al: Monoclonal antibody G 250 recognizes a determinant present in renal-cell carcinoma and absent from normal kidney. Int J Cancer 38:489-494, 1986
6. Li G, Passebosc-Faure K, Lambert C, et al: The expression of G250/mn/CA9 antigen by flow cytometry: Its possible implication for detection of micrometastatic renal cancer cells. Clin Cancer Res 7:89-92, 2001
7. Wykoff CC, Beasley NJ, Watson PH, et al: Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res 60:7075-7083, 2000
8. Maxwell PH, Wiesener MS, Chang GW, et al: The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399:271-275, 1999
9. Bleumer I, Knuth A, Oosterwijk E, et al: A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients. Br J Cancer 90:985-990, 2004
10. Bleumer I, Oosterwijk E, Oosterwijk-Wakka JC, et al: A clinical trial with chimeric monoclonal antibody WX-G250 and low dose interleukin-2 pulsing scheme for advanced renal cell carcinoma. J Urol 175:57-62, 2006
11. 131I-labeled chimeric monoclonal antibody G250. Clin Cancer Res 5:3268s-3274s, 1999 (suppl)
12. 131I-cG250 in patients with metastasized clear cell renal cell carcinoma. J Clin Oncol 23:6540-6548, 2005
13. 18F]FDG-PET imaging in patients with metastatic renal cell carcinoma: A comparative study. Nucl Med Commun 23:229-236, 2002
14. Brouwers AH, Buijs WCAM, Oosterwijk E, et al: Targeting of metastatic renal cell carcinoma with the chimeric monoclonal antibody G250 labeled with 131I or 111In: An intrapatient comparison. Clin Cancer Res 9:3953s-3960s, 2003 (suppl)